Quest Diagnostics to Launch $1.2B Senior Notes Offering | GenomeWeb

NEW YORK (GenomeWeb) – Quest Diagnostics today said that it plans to offer $1.2 billion in senior notes.

The Madison, NJ-based clinical lab firm said the offering is being made pursuant to a shelf registration filed with the US Securities and Exchange Commission. Goldman Sachs, JP Morgan Securities, Morgan Stanley, and Wells Fargo Securities will be the joint book-running managers for the offering.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A Karmagenes researcher has lost his position after reportedly admitting to data fabrication, according to Retraction Watch.

Two neuroscientists write in Nature News that solving the "reproducibility crisis" in science may require changing the requirements for publication.

In Nature this week: genomic analysis of prehistoric New Mexicans, a nanopore method for mapping DNA methylation, and more.

A new study finds that adding missing good bacteria to the skin microbiome of atopic dermatitis patients decreases Staphylococcus aureus colonization.